Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XENE 
Xenon Pharmaceuticals Inc (XENE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: XENE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.44% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.35B USD | Price to earnings Ratio - | 1Y Target Price 57.81 |
Price to earnings Ratio - | 1Y Target Price 57.81 | ||
Volume (30-day avg) 483156 | Beta 1.26 | 52 Weeks Range 30.58 - 46.00 | Updated Date 04/2/2025 |
52 Weeks Range 30.58 - 46.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.8% | Return on Equity (TTM) -27.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1727381729 | Price to Sales(TTM) 181.44 |
Enterprise Value 1727381729 | Price to Sales(TTM) 181.44 | ||
Enterprise Value to Revenue 10874.63 | Enterprise Value to EBITDA -11.81 | Shares Outstanding 76542800 | Shares Floating 70775310 |
Shares Outstanding 76542800 | Shares Floating 70775310 | ||
Percent Insiders 0.37 | Percent Institutions 103.48 |
Analyst Ratings
Rating 4.69 | Target Price 57.67 | Buy 5 | Strong Buy 11 |
Buy 5 | Strong Buy 11 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xenon Pharmaceuticals Inc
Company Overview
History and Background
Xenon Pharmaceuticals Inc. was founded in 1996. Initially focused on gene discovery, it has evolved into a biopharmaceutical company developing therapies for neurological disorders. Key milestones include successful clinical trials and strategic collaborations.
Core Business Areas
- Neurology: Focuses on developing novel therapies for neurological disorders, with a primary emphasis on epilepsy.
- Partnered Programs: Collaborates with other pharmaceutical companies to develop and commercialize therapies outside of neurology.
Leadership and Structure
The leadership team includes Ian Mortimer (President & CEO) and various VPs overseeing research, development, and commercial operations. The organizational structure is typical of a biopharmaceutical company, with distinct R&D, clinical, and commercial departments.
Top Products and Market Share
Key Offerings
- XEN1101 (active ingredient is ezogabine): A Kv7 potassium channel opener being developed for focal epilepsy and other neurological disorders. Clinical trials are ongoing. Competitors include established anti-epileptic drugs (AEDs) from companies like UCB (UCBJF) and Eisai (ESALY) and generic AEDs.
- Partnered programs (e.g., Takeda collaboration): Xenon collaborates with Takeda to develop therapies for neurological disorders. Revenue is generated through milestone payments and royalties. Competitors depend on the specific target the partnered drug addressess.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and patent protection. Demand for neurological therapies is growing due to an aging population and increasing prevalence of neurological disorders.
Positioning
Xenon is a mid-sized biopharmaceutical company specializing in neurological therapies. Their competitive advantage lies in their novel drug targets and expertise in neurological drug development.
Total Addressable Market (TAM)
The global epilepsy therapeutics market is expected to reach billions of dollars. Xenon is positioned to capture a portion of this market with its XEN1101 program. The total addressable market could be valued at between $6 billion and $8 billion USD by 2030.
Upturn SWOT Analysis
Strengths
- Novel drug targets
- Experienced management team
- Strong intellectual property portfolio
- Strategic partnerships
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High R&D costs
- Limited number of products currently on the market
Opportunities
- Expanding into new neurological indications
- Acquisition or in-licensing of new drug candidates
- Partnering with larger pharmaceutical companies for commercialization
- Favorable regulatory changes
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Patent expiration
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- UCBJF
- ESALY
- GRTS
- NEWR
Competitive Landscape
Xenon is a smaller player compared to established pharmaceutical companies like UCB and Eisai. However, its focus on novel drug targets and strategic partnerships gives it a competitive edge in certain areas.
Major Acquisitions
None (that are noteworthy)
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial advancements and revenue from partnered programs.
Future Projections: Future growth is dependent on the successful development and commercialization of XEN1101 and other pipeline candidates. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing XEN1101 through clinical trials and exploring new therapeutic targets.
Summary
Xenon Pharmaceuticals is a biopharmaceutical company with promise in the neurological space, particularly epilepsy. The company's strengths lie in its novel drug targets and partnerships. However, it faces risks associated with clinical trial outcomes and competition. Securing commercialization would greatly benefit the company.
Similar Companies
GRTS
Gritstone Oncology Inc
GRTS
Gritstone Oncology Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Burnaby, BC, Canada | ||
IPO Launch date 2014-11-05 | President, CEO & Director Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.xenon-pharma.com |
Full time employees 316 | Website https://www.xenon-pharma.com | ||
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.